Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry ...

If you ever dreamed of having your brain hooked up to a collection of tubes, pumps, and laboratory gadgets within hours of ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

Shares of Krystal Biotech KRYS have risen 16% over the past three months against the industry’s 9.4% decline, driven by ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese ...

The structural advantages that allow China to conduct clinical trials more quickly and at lower costs should be leveraged to ...

This Biotech Stock Is Up 85%. FDA Has Agreed to Review a Skin Cancer Drug. Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...